Document is current
Any future updates will be listed below
-
Authors
Thaiprayoon, Apisitt
Chantarasorn, Yodpong
Oonanant, Worrapoj
Kasorn, Anongnard
Longsompurana, Phoomintara
Tapaneeyakorn, Satita
Riangrungroj, Pinpunya
Loison, Fabien
Kruse, Andrew C.
DeLisa, Matthew P.
Waraho-Zhmayev, Dujduan
-
Funding
Funding for this research was provided by:
National Research Council of Thailand (NRCT5-RGJ63006, Fiscal year 2024, Fiscal year 2024, Fiscal year 2024, Fiscal year 2024, Fiscal year 2024)
Navamindradhiraj University Research Fund (03/2563, 03/2563, 03/2563)
Asahi Glass Foundation
Thailand Science Research and Innovation (FRB670016/0164)
- License Information
-
More Information
Article History
Received: 30 May 2024
Accepted: 23 January 2025
First Online: 28 January 2025
Declarations
:
: M.P.D. has financial interests in Gauntlet, Inc., Glycobia, Inc., Resilience, Inc., UbiquiTX, Inc., and Versatope Therapeutics, Inc. M.P.D.‘s interests are reviewed and managed by Cornell University in accordance with their conflict-of-interest policies. All other authors declare no competing interests. A.C.K. is a cofounder and consultant for biotechnology companies Tectonic Therapeutic and Seismic Therapeutic, and also for the Institute for Protein Innovation, a nonprofit research institute. The other authors do not have any Competing-Interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.
: The study was approved by the Institutional Biosafety Committee of King Mongkut’s University of Technology (IBC-2020-031 and IBC-2023-004).
